SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pozniak Anton)
 

Sökning: WFRF:(Pozniak Anton) > (2014) > Ritonavir-boosted d...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006363naa a2200925 4500
001oai:lup.lub.lu.se:b5cc5f2a-c64d-43f3-91ec-8267746aa636
003SwePub
008171008s2014 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:130162442
0247 a https://lup.lub.lu.se/record/b5cc5f2a-c64d-43f3-91ec-8267746aa6362 URI
0247 a https://doi.org/10.1016/S0140-6736(14)61170-32 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1301624422 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Raffi, Françoisu University of Nantes4 aut
2451 0a Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
264 1c 2014
300 a 10 s.
520 a BACKGROUND: Standard first-line antiretroviral therapy for HIV-1 infection includes two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these drugs have limitations. We assessed the 96 week efficacy and safety of an NtRTI-sparing regimen.METHODS: Between August, 2010, and September, 2011, we enrolled treatment-naive adults into this randomised, open-label, non-inferiority trial in treatment-naive adults in 15 European countries. The composite primary outcome was change to randomised treatment before week 32 because of insufficient virological response, no virological response by week 32, HIV-1 RNA concentration 50 copies per mL or higher at any time after week 32; death from any cause; any new or recurrent AIDS event; or any serious non-AIDS event. Patients were randomised in a 1:1 ratio to receive oral treatment with 400 mg raltegravir twice daily plus 800 mg darunavir and 100 mg ritonavir once daily (NtRTI-sparing regimen) or tenofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir and 100 mg ritonavir once daily (standard regimen). This trial was registered with ClinicalTrials.gov, number NCT01066962.FINDINGS: Of 805 patients enrolled, 401 received the NtRTI-sparing regimen and 404 the standard regimen, with median follow-up of 123 weeks (IQR 112-133). Treatment failure was seen in 77 (19%) in the NtRTI-sparing group and 61 (15%) in the standard group. Kaplan-Meier estimated proportions of treatment failure by week 96 were 17·8% and 13·8%, respectively (difference 4·0%, 95% CI -0·8 to 8·8). The frequency of serious or treatment-modifying adverse events were similar (10·2 vs 8·3 per 100 person-years and 3·9 vs 4·2 per 100 person-years, respectively).INTERPRETATION: Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL.FUNDING: European Union Sixth Framework Programme, Inserm-ANRS, Gilead Sciences, Janssen Pharmaceuticals, Merck Laboratories.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a Adenine
653 a Adult
653 a Anti-HIV Agents
653 a CD4 Lymphocyte Count
653 a Cholesterol, HDL
653 a Cholesterol, LDL
653 a Darunavir
653 a Deoxycytidine
653 a Drug Resistance, Viral
653 a Drug Therapy, Combination
653 a Emtricitabine
653 a Female
653 a HIV Infections
653 a HIV-1
653 a Humans
653 a Kaplan-Meier Estimate
653 a Male
653 a Middle Aged
653 a Organophosphonates
653 a Pyrrolidinones
653 a Raltegravir Potassium
653 a Ritonavir
653 a Sulfonamides
653 a Tenofovir
653 a Treatment Outcome
653 a Comparative Study
653 a Journal Article
653 a Multicenter Study
653 a Randomized Controlled Trial
653 a Research Support, Non-U.S. Gov't
7001 a Babiker, Abdel G.u University College London4 aut
7001 a Richert, Laurau University of Bordeaux4 aut
7001 a Molina, Jean-Michelu Paris Diderot University,Saint-Louis Hospital, Paris4 aut
7001 a George, Elizabeth C.u University College London4 aut
7001 a Antinori, Andreau Lazzaro Spallanzani National Institute for Infectious Diseases4 aut
7001 a Arribas, Jose Ru University Hospital La Paz4 aut
7001 a Grarup, Jesperu University of Copenhagen,Copenhagen University Hospital4 aut
7001 a Hudson, Fleuru University College London4 aut
7001 a Schwimmer, Christineu University of Bordeaux4 aut
7001 a Saillard, Julietteu ANRS - France Recherche Nord & Sud Sida-HIV Hépatites virales4 aut
7001 a Wallet, Cédricku University of Bordeaux4 aut
7001 a Jansson, Per O.u University of Copenhagen4 aut
7001 a Allavena, Clotildeu University of Nantes4 aut
7001 a Van Leeuwen, Remkou Academic Medical Center of University of Amsterdam (AMC),Amsterdam Institute for Global Health and Development4 aut
7001 a Delfraissy, Jean-Françoisu Bicêtre Hospital4 aut
7001 a Vella, Stefanou Italian National Institute of Health (ISS)4 aut
7001 a Chêne, Genevièveu University of Bordeaux4 aut
7001 a Pozniak, Antonu Chelsea and Westminster Hospital4 aut
7001 a Odermarsky, Michalu Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)mi1050od
7102 a University of Nantesb University College London4 org
7102 a NEAT001/ANRS143 Study Group
7730 t The Lancetg 384:9958, s. 51-1942q 384:9958<51-1942x 1474-547X
8564 u http://dx.doi.org/10.1016/S0140-6736(14)61170-3y FULLTEXT
8564 8u https://lup.lub.lu.se/record/b5cc5f2a-c64d-43f3-91ec-8267746aa636
8564 8u https://doi.org/10.1016/S0140-6736(14)61170-3
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:130162442

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy